Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Successfully removed peanut from the child’s left lung through bronchoscopy
Acute asthma attack is a common cause of admission to emergency departments (EDs) among children, and triage by severity is important for determining appropriate clinical treatment
Positive opinion could expand the role of Cosentyx (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EU
The partnership will further strengthen Olympus leadership in the diagnosis and staging of liver disease
Subscribe To Our Newsletter & Stay Updated
